Future prospective multicenter cohorts should enroll diverse COPD patients with acute lower respiratory infections across severity strata, employing standardized CRP assays alongside inflammatory mediators (IL-6, TNF-α). The gene discussed is CRP; the disease is respiratory tract infectious disorder.